Across TCGA pan-cancer cohorts, TTBK2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TTBK2 data layer compared with 26 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TTBK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTBK2 expression acts as an unfavorable survival marker.
PDAC, GBM, and LUAD are the cancer types where TTBK2 mass-spec protein most reproducibly stratifies survival.